NOTICE OF INTENT TO AWARD SOLE SOURCE
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA), specifically the FDA Office of Acquisition & Grant Services, has issued a Notice of Intent to Award a Sole Source Contract to GERSTEL, Inc. for preventative maintenance, repair, and support services for GERSTEL Multipurpose Robotic Sampler Workstations. This action is based on the determination that GERSTEL, Inc. is the only responsible source. Other firms interested in demonstrating their capability to provide these services must submit evidence by June 23, 2026, at 10 AM EST.
Scope of Work
The intended contract covers comprehensive preventative maintenance inspections, repair services, and technical support for GERSTEL Multipurpose Robotic Sampler Workstations. This includes all necessary labor, parts, consumables, travel, and OEM-required service activities to ensure the optimal functioning of these critical systems.
Contract & Timeline
- Type: Notice of Intent to Award Sole Source (Special Notice)
- Authority: FAR 13.106-1(b) and/or 10 U.S.C. 3204 (other than full and open competition due to only one responsible source).
- Duration: A base year plus four (4) option years.
- NAICS Code: 811210 (Electronic and Precision Equipment Repair and Maintenance).
- Set-Aside: Not applicable (sole source intent).
- Published Date: June 16, 2026
- Response Deadline: June 23, 2026, at 10 AM EST.
Submission & Evaluation
This notice is NOT a request for quotes or proposals. The Government's determination not to compete this action is at its discretion. Firms desiring consideration must submit clear and convincing evidence that competition would be advantageous to the Government, would not be cost or time prohibitive, and would not hinder the mission objective. Capability statements must be submitted within 7 days of the notice publication (by June 23, 2026). The Government will not be responsible for any costs incurred by responding.
Contact Information
Questions or comments regarding this Notice of Intent must be directed via email only to Contract Specialist Elena Tatarov at elena.tatarov@fda.hhs.gov. The subject line of the email must be: "Notice of Intent Questions Submission – FDA-26-1289292". Phone calls or voicemail messages will not be accepted or receive a response.